Beneficial effects of captopril in acute coxsackievirus B3 murine myocarditis.
- 1 March 1990
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 81 (3) , 1039-1046
- https://doi.org/10.1161/01.cir.81.3.1039
Abstract
To date, there is no universally accepted therapy for viral myocarditis. We investigated the effect of the angiotensin converting enzyme inhibitor captopril on both early and late phases of coxsackievirus murine myocarditis. Mice were infected with coxsackievirus B3 and were divided into two main protocols. Mice in the early treatment protocol (n = 30) were treated on day 1 after infection with either captopril or saline through day 6 of infection and euthanized on day 6 of infection. In the late treatment protocol, mice (n = 60) were treated starting on day 10 of infection through day 30 of infection with either captopril or saline. Mice were killed on days 20 and 30 of infection. In the early treatment protocol, heart weight was 67 +/- 14 mg in the captopril-treated group versus 98 +/- 17 mg in the control group (p less than 0.0001). The degree of inflammation, necrosis, and dystrophic calcification assessed with a semiquantitative histological score was significantly less in the captopril-treated group. The degree of pathological involvement determined by planimetry of histological sections was 8.1 +/- 7.2% for the captopril-treated group versus 22.5 +/- 10.0% for the saline-treated group (p less than 0.0001). In the late treatment protocol, captopril also caused a reduction in heart weight as compared with controls at day 20 (116 +/- 21 mg in captopril-treated group vs. 166 +/- 34 mg in controls, p less than 0.0001) and also at day 30 (136 +/- 23 mg in captopril-treated group vs. 185 +/- 48 mg in controls, p less than 0.004). On days 20 and 30 of infection, the degree of inflammation, necrosis, and dystrophic calcification was similar in both groups. We conclude that captopril is beneficial in acute coxsackievirus B3 murine myocarditis because it reduces heart weight and necrosis when administered early and reduces heart weight when administered in a delayed manner.This publication has 28 references indexed in Scilit:
- Effect of Captopril on Progressive Ventricular Dilatation after Anterior Myocardial InfarctionNew England Journal of Medicine, 1988
- Dissociation of the prostaglandin and renin angiotensin systems during captopril therapy for chronic congestive heart failure secondary to coronary artery diseaseThe American Journal of Cardiology, 1987
- Dependence of enhanced maximal exercise performance on increased peak skeletal muscle perfusion during long-term captopril therapy in heart failureJournal of the American College of Cardiology, 1987
- Vasopressin, renin and norepinephrine levels before and after captopril administration in patients with congestive heart failure due to idiopathic dilated cardiomyopathyThe American Journal of Cardiology, 1986
- Effect of Captopril on Transplanted Schistosome Egg Granulomas in SkinJournal of Investigative Dermatology, 1985
- Cardiovascular effects and regional blood flow distribution associated with angiotensin converting enzyme inhibition (captopril) in essential hypertensionThe American Journal of Cardiology, 1985
- EFFECTS OF CAPTOPRIL ON ABNORMALITIES OF THE PERIPHERAL CIRCULATION AND RESPIRATORY FUNCTION IN PATIENTS WITH SEVERE HEART FAILUREThe Lancet, 1984
- Acute effects of captopril on cardiopulmonary hemodynamics and renin-angiotensin-aldosterone and bradykinin profile in hypertensionAmerican Heart Journal, 1983
- Haemodynamic and hormonal effects of captopril in primary pulmonary hypertension.Heart, 1982
- Age-Dependent Pathogenicity of Group B Coxsackieviruses in Swiss-Webster Mice: Infectivity for Myocardium and PancreasThe Journal of Infectious Diseases, 1980